SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Up 2,400.0% in November

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 2,500 shares, a growth of 2,400.0% from the October 31st total of 100 shares. Based on an average daily volume of 15,200 shares, the days-to-cover ratio is currently 0.2 days.

SAB Biotherapeutics Price Performance

SAB Biotherapeutics stock remained flat at $0.07 during trading hours on Wednesday. The company’s stock had a trading volume of 5,216 shares, compared to its average volume of 19,303. SAB Biotherapeutics has a 1-year low of $0.01 and a 1-year high of $0.19. The stock has a 50-day simple moving average of $0.05 and a 200-day simple moving average of $0.04.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.